Soleno Therapeutics (SLNO) Change in Account Payables (2013 - 2026)

Soleno Therapeutics (SLNO) has 14 years of Change in Account Payables data on file, last reported at -$3.0 million in Q1 2026.

• Change in Account Payables for Q1 2026 came in at -$3.0 million, up 10.97% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.0 million (up 257.3% YoY), and the FY2025 annual result was $3.6 million, down 36.32% from the prior year.
• Change in Account Payables eased to -$3.0 million in Q1 2026 per SLNO's latest filing, from $4.3 million in the prior quarter.
• Over five years, Change in Account Payables peaked at $4.9 million in Q1 2024 and troughed at -$4.3 million in Q2 2024.
• A 5-year average of $365235.3 and a median of $198000.0 in 2022 frame the typical range for Change in Account Payables.
• On a YoY basis, Change in Account Payables climbed as much as 7482.35% in 2024 and fell as far as 733.92% in 2024.
• A 5-year view of Change in Account Payables shows it stood at -$547000.0 in 2022, then surged by 106.22% to $34000.0 in 2023, then surged by 7482.35% to $2.6 million in 2024, then jumped by 66.25% to $4.3 million in 2025, then tumbled by 169.3% to -$3.0 million in 2026.
• Business Quant data shows SLNO's Change in Account Payables at -$3.0 million in Q1 2026, $4.3 million in Q4 2025, and $1.9 million in Q3 2025.